Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment

BMC Cardiovascular Disorders

Ann-Christine Syvänen²  Thomas Kahan¹  Lars Berglund³  Lisa Kurland²  Lars Lind⁴  Ulrika Liljedahl² 

[1] Division of Internal Medicine, Karolinska Institute, Danderyd Hospital, 182 88 Stockholm, Sweden;Department of Medical Sciences, Uppsala University, Uppsala University Hospital, Entrance 70, 3rd floor, 751 85 Uppsala, Sweden;Uppsala Clinical Research Center (UCR), Uppsala University, 751 85 Uppsala, Sweden;Astra Zeneca Research & Development Mölndal, 431 83 Mölndal, Sweden

关键词: genotyping;    minisequencing;    lipids;    pharmacogenetics;    Antihypertensive treatment;   

Others  :  1088593
DOI  :  10.1186/1471-2261-4-16

 received in 2004-06-02, accepted in 2004-09-28,  发布年份 2004

【 摘 要 】

Background

Dyslipidemia has been associated with hypertension. The present study explored if polymorphisms in genes encoding proteins in lipid metabolism could be used as predictors for the individual response to antihypertensive treatment.

Methods

Ten single nucleotide polymorphisms (SNP) in genes related to lipid metabolism were analysed by a microarray based minisequencing system in DNA samples from ninety-seven hypertensive subjects randomised to treatment with either 150 mg of the angiotensin II type 1 receptor blocker irbesartan or 50 mg of the β₁-adrenergic receptor blocker atenolol for twelve weeks.

Results

The reduction in blood pressure was similar in both treatment groups. The SNP C711T in the apolipoprotein B gene was associated with the blood pressure response to irbesartan with an average reduction of 19 mmHg in the individuals carrying the C-allele, but not to atenolol. The C16730T polymorphism in the low density lipoprotein receptor gene predicted the change in systolic blood pressure in the atenolol group with an average reduction of 14 mmHg in the individuals carrying the C-allele.

Conclusions

Polymorphisms in genes encoding proteins in the lipid metabolism are associated with the response to antihypertensive treatment in a drug specific pattern. These results highlight the potential use of pharmacogenetics as a guide for individualised antihypertensive treatment, and also the role of lipids in blood pressure control.

【 授权许可】

   
2004 Liljedahl et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Cadman PE, O'Connor DT: Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens 2003, 12:61-70.
• [2]Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E: Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens 2001, 19:1-11.
• [3]Turner ST, Boerwinkle E: Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics 2003, 4:53-65.
• [4]Laragh JH, Lamport B, Sealey J, Alderman MH: Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988, 12:223-226.
• [5]Lind L, Berne C, Andersson PE, Hanni A, Lithell H: Is insulin resistance a predictor of the blood pressure response to anti-hypertensive treatment? J Hum Hypertens 1995, 9:759-763.
• [6]Koopmans RP, Insel PA, Michel MC: Pharmacogenetics of hypertension treatment: a structured review. Pharmacogenetics 2003, 13:705-713.
• [7]Pausova Z, Gossard F, Gaudet D, Tremblay J, Kotchen TA, Cowley AW, Hamet P: Heritability estimates of obesity measures in siblings with and without hypertension. Hypertension 2001, 38:41-47.
• [8]Fagard RH, Loos RJ, Beunen G, Derom C, Vlietinck R: Influence of chorionicity on the heritability estimates of blood pressure: a study in twins. J Hypertens 2003, 21:1313-1318.
• [9]Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Attshuler D: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409:928-933.
• [10]Cardon LR, Idury RM, Harris TJ, Witte JS, Elston RC: Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 2000, 10:503-510.
• [11]Bader JS: The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics 2001, 2:11-24.
• [12]Doris PA: Hypertension genetics, single nucleotide polymorphisms, and the common disease:common variant hypothesis. Hypertension 2002, 39:323-331.
• [13]Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Hagg A, Lind L: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens 2001, 19:1783-1787.
• [14]Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nystrom F, Hagg A, Lind L: Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002, 15:389-393.
• [15]Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvanen AC, Lind L: Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004, 17:8-13.
• [16]Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, Nystrom F, Lind L, Syvanen AC: A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003, 13:7-17.
• [17]Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, Muller-Brunotte R, Nystrom F, Ohman KP, Osbakken MD, Ostergern J: Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001, 19:1167-1176.
• [18]Syvanen AC, Sajantila A, Lukka M: Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing. Am J Hum Genet 1993, 52:46-59.
• [19]Churchill GA, Doerge RW: Empirical threshold values for quantitative trait mapping. Genetics 1994, 138:963-971.
• [20]Chatterton JE, Schlapfer P, Butler E, Gutierrez MM, Puppione DL, Pullinger CR, Kane JP, Curtiss LK, Schumaker VN: Identification of apolipoprotein B100 polymorphisms that affect low-density lipoprotein metabolism: description of a new approach involving monoclonal antibodies and dynamic light scattering. Biochemistry 1995, 34:9571-9580.
• [21]Steer P, Hulthe J, Miligard J, Sarabi DM, Basu S, Vessby B, Lind L: Endothelial vasodilatory function is predicted by circulating apolipoprotein B and HDL in healthy humans. Lipids 2002, 37:1135-1140.
• [22]von zur Muhlen B, Kahan T, Hagg A, Millgard J, Lind L: Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens 2001, 19:1813-1818.
• [23]Stepniakowski KT, Goodfriend TL, Egan BM: Fatty acids enhance vascular alpha-adrenergic sensitivity. Hypertension 1995, 25:774-778.
• [24]Haastrup AT, Stepniakowski KT, Goodfriend TL, Egan BM: Intralipid enhances alpha1-adrenergic receptor mediated pressor sensitivity. Hypertension 1998, 32:693-698.
• [25]Stojiljkovic MP, Zhang D, Lopes HF, Lee CG, Goodfriend TL, Egan BM: Hemodynamic effects of lipids in humans. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1674-9.
• [26]Lopes HF, Stojiljkovic MP, Zhang D, Goodfriend TL, Egan BM: The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents. Am J Hypertens 2001, 14:1032-1037.
• [27]Stepniakowski KT, Sallee FR, Goodfriend TL, Zhang Z, Egan BM: Fatty acids enhance neurovascular reflex responses by effects on alpha 1-adrenoceptors. Am J Physiol 1996, 270:R1340-6.